ISSN: 1859 - 2872
Effective of treatment of chronic urticarial with desloratadin combined with montelukast
Main Article Content
Keywords
Abstract
Objective: To evaluate the results of treatment of chronic urticaria with desloratadine combined montelukast. Subject and method: Clinical intervention study, randomized controlled on 92 patients diagnosed with chronic urticaria at the 108 Military Central Hospital from October 2021 to October 2023. Patients were randomly assigned according to the odd-even rule into 2 treatment groups: Researchers group (desloratadine 10mg-montelukast 10mg) and opposite group (desloratadine 10mg). Compare treatment effectiveness in terms of itching severity, itching frequency, number of papules, USA7 score, TSS, Cu-QoL and side effects at 4 weeks and 8 weeks after starting treatment. Result: The 2 regimens were effective in all evaluation criteria at 4 weeks and 8 weeks after starting treatment. The number of papules in researchers group decreased more than in opposite group (p<0.05). However, the criteria of itching level, papule size, disease frequency, TSS score, USA7 and Cu-QoL had no statistically significant differences between the 2 groups at the time of the study. No significant side effects were noted in the 2 treatment groups. Conclusion: Montelukast-desloratadine is a more effective regimen and has a tolerability level equivalent to a standard antihistamine regimen
Article Details
References
2. Bracken SJ, Abraham S, Macleod AS (2019) Autoimmune Theories of Chronic Spontaneous Urticaria. Front Immunol 10:627. doi: 10.3389/fimmu.2019.00627.
3. Nguyễn Năng An (2003) Tình hình dị ứng thuốc ở nước ta, đề xuất những biện pháp can thiệp. Đề tài cấp nhà nước. Bộ Khoa học Công nghệ và Môi trường, tr. 50-52.
4. Yun J, Katelaris CH, Weerasinghe A (2011) Impact of chronic urticaria on the quality of life in Australian and Sri Lankan populations. Asia Pac Allergy 1(1): 25-29.
5. Zuberbier T, Asero R, Bindslev-Jensen C, Walter Canonica G, Church MK, Giménez-Arnau AM, Grattan CEH, Kapp A, Maurer M, Merk HF, Rogala B, Saini S, Sánchez-Borges M, Schmid-Grendelmeier P, Schünemann H, Staubach P, Vena GA, Wedi B (2009) EAACI/GA²LEN/EDF/WAO guideline: Management of urticaria. Allergy 64: 1417-1426.
6. Chow SKW (2012) Management of chronic urticaria in Asia: 2010 AADV consensus guidelines. Asia Pac Allergy 2(2): 149-160.
7. Ngô Thị Minh Nguyệt (2020) Kết quả điều trị mày đay mạn tự phát bằng colchicin kết hợp desloratadin. Luận văn thạc sĩ Y học, Trường Đại học Y Hà Nội.
8. Nettis E, Colanardi MC, Soccio AL, Ferrannini A, Vacca A (2004) Desloratadine in combination with montelukast in the treatment of chronic urticaria: A randomized, double‐blind, placebo‐controlled study. Clinical & Experimental Allergy 34(9): 1401-1407.
9. Di Lorenzo G, Pacor ML, Mansueto P, Esposito Pellitteri M, Lo Bianco C, Ditta V, Martinelli N, Rini GB (2004) Randomized placebo-controlled trial comparing desloratadine and montelukast in monotherapy and desloratadine plus montelukast in combined therapy for chronic idiopathic urticaria. Journal of Allergy and Clinical Immunology 114(3): 619-625.
10. Sarkar TK, Sil A, Pal S, Ghosh C, Das NK (2017) Effectiveness and safety of levocetirizine 10mg versus a combination of levocetirizine 5mg and montelukast 10 mg in chronic urticaria resistant to levocetirizine 5 mg: A double-blind, randomized, controlled trial. Indian J Dermatol Venereol Leprol. 83(5): 561-568.
Article Sidebar
